

Recovery and Allocation Summary Totals - Actual and Estimated (Revised 01-01-2024)

Opioid Settlement and Bankruptcy Actual and Estimated Annual Recoveries and Allocations Pursuant to the One Nevada Agreement

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement/Bankruptcy Name	Estimated/Actual Recovery Year	Estimated/Actual Recovery Month	Signatories of One Nevada Agreement Recoveries	Costs (Deducted)	Costs (Through Settlement)	Common Benefit Fund (Deducted)	Total Amount to be Allocated	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation After Fees
Janssen - J&J	2022	April	\$ 50,833,353.00	\$ 8,397,545.43	\$ -	\$ -	\$ 42,435,807.57	\$ 7,037,053.92	\$ -	\$ 35,398,753.65
Distributors	2022	August	\$ 9,897,161.96	\$ -	\$ -	\$ -	\$ 9,897,161.96	\$ 1,641,228.64	\$ -	\$ 8,255,933.32
Distributors	2022	September	\$ 10,401,434.73	\$ -	\$ -	\$ -	\$ 10,401,434.73	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
American Drug Stores	2022	November	\$ 1,500,000.00	\$ -	\$ -	\$ -	\$ 1,500,000.00	\$ 337,815.52	\$ -	\$ 1,162,184.48
Mallinckrodt (BK)	2022	November	\$ 1,849,733.70	\$ -	\$ -	\$ -	\$ 1,849,733.70	\$ 416,579.22	\$ -	\$ 1,433,154.48
Mallinckrodt (BK)	2022	November	\$ 40.00	\$ -	\$ -	\$ -	\$ 40.00	\$ -	\$ -	\$ 40.00
Distributors	2023	July	\$ 10,401,434.73	\$ -	\$ -	\$ -	\$ 10,401,434.73	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
Allergan	2023	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
CVS	2023	August	\$ 15,185,877.23	\$ -	\$ 4,000,000.00	\$ 1,422,917.12	\$ 13,762,960.11	\$ -	\$ 14,713,742.58	\$ 13,762,960.11
Mallinckrodt (BK)	2023	October	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (416,579.22)	\$ -	\$ 416,579.22
Mallinckrodt (BK)	2023	December	\$ 2,176,204.35	\$ -	\$ -	\$ -	\$ 2,176,204.35	\$ -	\$ -	\$ 2,176,204.35
Walgreens	2023	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45	\$ -	\$ -	\$ 11,574,061.45
Teva	2024	January	\$ -	\$ -	\$ 3,717,924.13	\$ -	\$ -	\$ -	\$ -	\$ -
Masters	2024	February	\$ 1,428,552.26	\$ -	\$ -	\$ -	\$ 1,428,552.26	\$ 331,123.20	\$ -	\$ 1,097,429.06
Walmart	2024	February	\$ 12,247,794.12	\$ -	\$ 3,314,969.52	\$ -	\$ 12,247,794.12	\$ -	\$ 3,880,607.85	\$ 12,247,794.12
Walmart	2024	March	\$ 19,016,311.93	\$ -	\$ -	\$ -	\$ 19,016,311.93	\$ -	\$ -	\$ 19,016,311.93
Purdue (BK)	2024	July	\$ 56,000,000.00	\$ -	\$ -	\$ -	\$ 56,000,000.00	\$ 12,980,203.37	\$ -	\$ 43,019,796.63
Distributors	2024	July	\$ 13,018,868.99	\$ -	\$ -	\$ -	\$ 13,018,868.99	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2024	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ 3,287,105.21	\$ 3,403,705.25
Teva	2024	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68	\$ -	\$ -	\$ 4,985,372.68
CVS	2024	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11	\$ -	\$ 14,713,742.58	\$ 13,762,960.11
Walgreens	2024	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45	\$ -	\$ 16,514,990.87	\$ 11,574,061.45
Walmart	2025	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78	\$ -	\$ -	\$ 241,732.78
Janssen - J&J	2025	April	\$ 2,675,439.64	\$ -	\$ -	\$ -	\$ 2,675,439.64	\$ 443,663.37	\$ -	\$ 2,231,776.27
Distributors	2025	July	\$ 13,018,868.99	\$ -	\$ -	\$ -	\$ 13,018,868.99	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2025	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2025	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68	\$ -	\$ -	\$ 4,985,372.68
CVS	2025	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11	\$ -	\$ 14,713,742.58	\$ 13,762,960.11
Walgreens	2025	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45	\$ -	\$ 16,514,990.87	\$ 11,574,061.45
Walmart	2026	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78	\$ -	\$ -	\$ 241,732.78
Distributors	2026	July	\$ 13,018,868.99	\$ -	\$ -	\$ -	\$ 13,018,868.99	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2026	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2026	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68	\$ -	\$ -	\$ 4,985,372.68
CVS	2026	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11	\$ -	\$ 14,713,742.58	\$ 13,762,960.11
Walgreens	2026	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45	\$ -	\$ 16,514,990.87	\$ 11,574,061.45
Walmart	2027	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78	\$ -	\$ -	\$ 241,732.78
Distributors	2027	July	\$ 13,018,868.99	\$ -	\$ -	\$ -	\$ 13,018,868.99	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2027	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2027	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2027	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2027	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ 16,514,990.88	\$ 14,596,002.43
Walmart	2028	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78	\$ -	\$ -	\$ 241,732.78
Distributors	2028	July	\$ 15,311,758.47	\$ -	\$ -	\$ -	\$ 15,311,758.47	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Allergan	2028	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2028	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2028	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2028	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Walmart	2029	July	\$ 15,311,758.47	\$ -	\$ -	\$ -	\$ 15,311,758.47	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Distributors	2029	July	\$ 3,786,987.57	\$ -	\$ -	\$ -	\$ 3,786,987.57	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2029	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2029	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2029	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2030	July	\$ 15,311,758.47	\$ -	\$ -	\$ -	\$ 15,311,758.47	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Teva	2030	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2030	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2030	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2031	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2031	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2031	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2031	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2032	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2032	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
CVS	2032	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2032	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2033	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2033	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
Walgreens	2033	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2034	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2034	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04	\$ -	\$ 5,504,996.96	\$ 1,495,003.04
Walgreens	2034	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2035	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2035	July	\$ 7,000,000.00	\$ -	\$ -	\$ -	\$ 7,000,000.00	\$ -	\$ -	\$ 7,000,000.00
Walgreens	2035	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2036	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2036	July	\$ 7,000,000.00	\$ -	\$ -	\$ -	\$ 7,000,000.00	\$ -	\$ -	\$ 7,000,000.00
Walgreens	2036	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2037	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2037	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00	\$ -	\$ -	\$ 9,000,000.00
Walgreens	2037	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43	\$ -	\$ -	\$ 14,596,002.43
Distributors	2038	July	\$ 12,871,078.28	\$ -	\$ -	\$ -	\$ 12,871,078.28	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2038	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00	\$ -	\$ -	\$ 9,000,000.00
Teva	2039	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00	\$ -	\$ -	\$ 9,000,000.00
Teva	2040	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00	\$ -	\$ -	\$ 9,000,000.00
Teva	2041	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00	\$ -	\$ -	\$ 9,000,000.00
Teva	2042	July	\$ 27,000,000.00	\$ -	\$ -	\$ -	\$ 27,000,000.00	\$ -	\$ -	\$ 27,000,000.00
Teva	2043	July	\$ 27,000,000.00	\$ -	\$ -	\$ -	\$ 27,000,000.00	\$ -	\$ -	\$ 27,000,000.00
Subtotals			\$ 923,641,515.21	\$ 8,397,545.43	\$ 11,032,893.65	\$ 19,378,456.26	\$ 895,865,513.52	\$ 62,231,816.78	\$ 161,408,879.97	\$ 833,633,696.74
Additional Information - Outside the One Nevada Agreement										
McKinsey (State Only)	2021	September	\$ 45,000,000.00	\$ 16,538,249.51	\$ -	\$ -	\$ 28,461,750.49	\$ 5,407,732.59	\$ -	\$ 23,054,017.90
Janssen - J&J (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (4,603,844.83)	\$ -	\$ -
Distributors (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (15,432,662.80)	\$ -	\$ -
Janssen - J&J (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (302,274.46)	\$ -	\$ -
Distributors (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (1,302,503.98)	\$ -	\$ -
Distributors (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (589,362.17)	\$ -	\$ -
Janssen - J&J (State Fee Fund)	2024	January	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (90.30)	\$ -	\$ -
Janssen - J&J (State Fee Fund)	2024	August	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (302,274.46)	\$ -	\$ -
Total Payments and Allocations			\$ 968,641,515.21	\$ 24,935,794.94	\$ 11,032,893.65	\$ 19,378,456.26	\$ 924,327,264.01	\$ 45,106,536.37	\$ 161,408,879.97	\$ 856,687,714.64
			\$ 1,141,083,288.83		\$ 35,968,688.59				\$ 206,515,416.34	
		Total Recoveries							Total Attorney Fees	